Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
BioCryst Pharmaceuticals Inc - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
BCRX
Nasdaq
2836
https://www.biocryst.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for BioCryst Pharmaceuticals Inc
With 80% ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) boasts of strong institutional backing
- Apr 22nd, 2024 12:04 pm
BioCryst to Report First Quarter 2024 Financial Results on May 6
- Apr 22nd, 2024 11:00 am
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Brazilian Health Regulatory Agency
- Apr 17th, 2024 8:30 am
12 Best Depressed Stocks To Buy in 2024
- Apr 10th, 2024 10:09 pm
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Apr 3rd, 2024 11:00 am
BioCryst to Present at Upcoming Investor Conferences
- Mar 25th, 2024 8:01 pm
13 Best Biotech Stocks To Buy Under $20
- Mar 13th, 2024 11:07 am
Hidden Penny Gems: 7 Stocks With Triple-Digit Growth Prospects
- Mar 1st, 2024 1:29 pm
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript
- Feb 28th, 2024 3:47 pm
BioCryst Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations
- Feb 27th, 2024 10:07 am
Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call
- Feb 27th, 2024 9:05 am
BioCryst Pharmaceuticals (BCRX) Q4 2023 Earnings Call Transcript
- Feb 26th, 2024 9:45 pm
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
- Feb 26th, 2024 1:10 pm
BioCryst Pharmaceuticals Inc (BCRX) Reports Growth in ORLADEYO Revenue and Projects ...
- Feb 26th, 2024 12:32 pm
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
- Feb 26th, 2024 12:00 pm
BioCryst Presents New Real-world Data Showing Rapid, Substantial and Sustained HAE Attack Rate Reductions After Beginning ORLADEYO® (berotralstat) Treatment
- Feb 23rd, 2024 12:00 pm
BioCryst Launches ORLADEYO® (berotralstat) in Italy
- Feb 19th, 2024 12:54 pm
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
- Feb 12th, 2024 12:00 pm
BioCryst to Present New ORLADEYO® (berotralstat) Real-world Data at 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting
- Feb 5th, 2024 12:00 pm
BioCryst (BCRX) Moves 25.6% Higher: Will This Strength Last?
- Jan 9th, 2024 2:25 pm
Scroll